RT Journal Article
SR Electronic
T1 Versatile and flexible microfluidic qPCR test for high-throughput SARS-CoV-2 and cellular response detection in nasopharyngeal swab samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228437
DO 10.1101/2020.11.09.20228437
A1 Fassy, Julien
A1 Lacoux, Caroline
A1 Leroy, Sylvie
A1 Noussair, Latifa
A1 Hubac, Sylvain
A1 Degoutte, Aurélien
A1 Vassaux, Georges
A1 Leclercq, Vianney
A1 Rouquié, David
A1 Marquette, Charles-Hugo
A1 Rottman, Martin
A1 Touron, Patrick
A1 Corbel, Antoinette Lemoine
A1 Herrmann, Jean-Louis
A1 Barbry, Pascal
A1 Nahon, Jean-Louis
A1 Zaragosi, Laure-Emmanuelle
A1 Mari, Bernard
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228437.abstract
AB The emergence and quick spread of SARS-CoV-2 has pointed at a low capacity response for testing large populations in many countries, in line of material, technical and staff limitations. The traditional RT-qPCR diagnostic test remains the reference method and is by far the most widely used test. These assays are limited to a couple of probe sets, require large sample PCR reaction volumes, along with an expensive and time-consuming RNA extraction steps. Here we describe a quantitative nanofluidic assay that overcomes some of these shortcomings, based on the Biomark instrument from Fluidigm. This system offers the possibility of performing 4608 qPCR end-points in a single run, equivalent to 192 clinical samples combined with 12 pairs of primers/probe sets in duplicate, thus allowing the monitoring in addition to SARS-CoV-2 probes of other pathogens and/or host cellular responses (virus receptors, response markers, microRNAs). Its 10 nL range volume is compatible with sensitive and reproducible reactions that can be easily and cost-effectively adapted to various RT-qPCR configurations and sets of primers/probe. Finally, we also evaluated the use of inactivating lysis buffers composed of various detergents in the presence or absence of proteinase K to assess the compatibility of these buffers with a direct reverse transcription enzymatic step and we propose several procedures, bypassing the need for RNA purification. We advocate that the combined utilization of an optimized processing buffer and a high-throughput real-time PCR device would contribute to improve the turn-around-time to deliver the test results to patients and increase the SARS-CoV-2 testing capacities.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://dx.doi.org/10.17504/protocols.io.bd3ii8ke https://dx.doi.org/10.17504/protocols.io.bnx4mfqw Funding StatementFundings from : the French Defence Innovation Agency, from the Plan Cancer 2018 ARN non-codants en cancerologie: du fondamental au translationnel (number 18CN045) and Canceropole PACA. The Biomark equipment was funded by Canceropole PACA and France Genomique (Commissariat aux Grands Investissements).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All necessary IRB approval are described in the Materials and Method: Ethics committee approval was obtained from the Comite de Protection des Personnes Sud Mediterranee V (registration # 2020-AO1050-39) on April 22, 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI state that all data are fully available without any restriction